SK Pharmteco bets big on cell, gene therapy

BARCELONA, Spain -- SK Pharmteco, SK Inc.’s contract bio-manufacturing subsidiary, said the company’s burgeoning cell and gene therapy (CGT) business will become its new growth engine.
“We continue to expand our CGT business, and the capacity we are building over the next years will allow us to grow this business,” SK Pharmteco CEO Joerg Ahlgrimm said during a press conference Tuesday held on the sidelines of the Convention on Pharmaceutical Ingredients (CPHI) Worldwide, the world’s largest pharma trade show that kicked off earlier this week in Barcelona, Spain.
“The goal is to make the CGT unit generate annual sales of over $10 billion in the next few years.”
Kim Yeon-tae, head of the Bio Investment Center of SK Inc., the investment unit of SK Group, admitted that the global CGT market growth has been delayed due to the slowing economy and reduced investments, but he stressed that the market could see a turnaround starting in 2024.
For the time being, SK Pharmteco, based in California, said it plans to focus on advancing its manufacturing and technological capabilities to respond promptly to the potential surge in demand.
In September, the firm became the largest shareholder of Philadelphia-based CGT contract manufacturer Center for Breakthrough Medicines after a series of investments worth $350 million. Adding to its 2021 acquisition of French viral vector contract manufacturer Yposkesi, the firm has secured its production bases both in Europe and the US.
“I believe that combining these two (Yposkesi and CBM) creates an offering which not many CDMOs (contract development and manufacturing organizations) have,” Ahlgrimm said. “Having the CGT manufacturing sites in the two major regions will help the company seek new clients.”
CBM, which has testing services for CGT developers, will also allow SK Pharmteco to bring more “complete offers” to pharmaceutical and biotech companies that are looking for a CDMO partner who can develop, test and produce their therapies.
While ramping up efforts to upgrade CGT capabilities, SK Pharmteco will continue to expand its CDMO capacity for active pharmaceutical ingredients.
Separately, the company recently secured an investment of $500 million in a preinitial public offering round. The CEO said the company will reinvest the money to diversify its business portfolio.
相关文章
'Do not open plane doors' warning mandated for planes in flight
South Korea's Transport Ministry said Tuesday it plans to revise its current ordinance on the o2023-12-04Plush bag charms in high demand among young Korean women
It may seem somewhat ironic to call a fluffy doll ornament adorning a handbag a "key ring," as it se2023-12-04Major retailer recalls over 50,000 pairs of shower shoes due to chemical hazard
Daiso, a discount store in Korea known for its wide selection of homeware goods, is recalling 53,0002023-12-04Exports of passenger cars up 16 pct in Q3 on eco
Exports of passenger cars moved up 16 percent in the third quarter of 2023 from a year earlier follo2023-12-04"조선의 샛별 여장군, 세계가 우러러 볼것"…北, 김주애도 우상화
북한이 김정은 북한 국무위원장의 딸 김주애를 ‘조선의 샛별’‘여장군’ 등으로 칭하며 내부적 우상화를 시작했다.자유아시아방송(RFA)은 지난 23일 노동당 조직지도부가 군사정찰위성2023-12-04- South Korean food giant CJ CheilJedang announced Monday that cumulative sales of its frozen fried ri2023-12-04
最新评论